ATE520406T1 - Kristalline form des ibandronat-natriums - Google Patents

Kristalline form des ibandronat-natriums

Info

Publication number
ATE520406T1
ATE520406T1 AT08002626T AT08002626T ATE520406T1 AT E520406 T1 ATE520406 T1 AT E520406T1 AT 08002626 T AT08002626 T AT 08002626T AT 08002626 T AT08002626 T AT 08002626T AT E520406 T1 ATE520406 T1 AT E520406T1
Authority
AT
Austria
Prior art keywords
ibandronate sodium
crystalline form
ray
crystalline
sodium
Prior art date
Application number
AT08002626T
Other languages
German (de)
English (en)
Inventor
Revital Lifshitz-Liron
Thomas Bayer
Judith Aronhime
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35968334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE520406(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE520406T1 publication Critical patent/ATE520406T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Artificial Filaments (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Secondary Cells (AREA)
  • Liquid Crystal Substances (AREA)
AT08002626T 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums ATE520406T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60402604P 2004-08-23 2004-08-23
US69086705P 2005-06-16 2005-06-16

Publications (1)

Publication Number Publication Date
ATE520406T1 true ATE520406T1 (de) 2011-09-15

Family

ID=35968334

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08002626T ATE520406T1 (de) 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums
AT05791142T ATE495747T1 (de) 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums und herstellungsverfahren dafür

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05791142T ATE495747T1 (de) 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums und herstellungsverfahren dafür

Country Status (12)

Country Link
US (1) US7563918B2 (enExample)
EP (2) EP1930011B1 (enExample)
JP (1) JP4559431B2 (enExample)
KR (2) KR20070043043A (enExample)
CN (1) CN101022812A (enExample)
AT (2) ATE520406T1 (enExample)
CA (1) CA2576659A1 (enExample)
DE (2) DE202005021414U1 (enExample)
ES (1) ES2358269T3 (enExample)
IL (1) IL181298A (enExample)
PT (2) PT1930011E (enExample)
WO (1) WO2006024024A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045637A1 (es) 2003-09-12 2005-11-02 Amgen Inc Formulacion de disolucion rapida de un compuesto activo frente a los receptores de calcio
LT2662380T (lt) * 2005-02-01 2019-03-12 Atnahs Pharma Uk Limited Ibandronato polimorfo a medicininis panaudojimas
EP2610261A1 (en) 2005-02-01 2013-07-03 F. Hoffmann-La Roche AG Ibandronate polymorph B
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
WO2008014510A2 (en) * 2006-07-28 2008-01-31 Dr. Reddy's Laboratories Limited Crystalline form a of ibandronic acid and process for the preparation
WO2008060609A1 (en) * 2006-11-16 2008-05-22 Teva Pharmaceutical Industries Ltd. Crystalline forms of ibandronate sodium
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
EP2144919B1 (en) 2007-04-11 2015-12-02 F. Hoffmann-La Roche AG Multi step synthesis of ibandronate
AU2008242788A1 (en) * 2007-04-19 2008-10-30 Dr. Reddy's Laboratories Ltd. Ibandronate sodium polymorphs
WO2009020483A1 (en) * 2007-08-09 2009-02-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of ibandronate sodium
EP2128166A1 (en) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Polymorphic forms of Ibandronate sodium and processes for preparation thereof
WO2009053445A2 (en) * 2007-10-26 2009-04-30 Chemo Ibérica, S.A. Polymorphic forms of ibandronate sodium and processes for preparation thereof
US20090118239A1 (en) * 2007-11-05 2009-05-07 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of ibandronate disodium
EP2180003A1 (en) 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
MX339194B (es) 2009-02-13 2016-05-16 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma.
US9192316B2 (en) 2009-05-15 2015-11-24 Nox Medical Systems and methods using flexible capacitive electrodes for measuring biosignals
WO2011016738A1 (en) 2009-08-05 2011-02-10 Zaklady Farmaceutyczne Polpharma Sa A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
US9059532B2 (en) 2010-06-25 2015-06-16 Nox Medical Biometric belt connector
KR101907434B1 (ko) 2010-09-03 2018-10-12 발네바 오스트리아 게엠베하 C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
WO2013179305A1 (en) * 2012-06-01 2013-12-05 Hetero Research Foundation Ibandronate sodium solid dispersion
WO2014170909A2 (en) 2013-04-01 2014-10-23 Hetero Research Foundation Process for pomalidomide
US10588550B2 (en) 2013-11-06 2020-03-17 Nox Medical Method, apparatus, and system for measuring respiratory effort
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
US10869619B2 (en) 2016-08-19 2020-12-22 Nox Medical Method, apparatus, and system for measuring respiratory effort of a subject
US11896386B2 (en) 2017-06-02 2024-02-13 Nox Medical Ehf Coherence-based method, apparatus, and system for identifying corresponding signals of a physiological study
US11602282B2 (en) 2017-09-08 2023-03-14 Nox Medical Ehf System and method for non-invasively determining an internal component of respiratory effort

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
JP2639721B2 (ja) 1988-12-27 1997-08-13 富士重工業株式会社 内燃機関の燃焼室
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
DE19637890A1 (de) * 1996-09-17 1998-03-19 Max Planck Gesellschaft Biphosphonat-Liposomen
DE19828450A1 (de) * 1998-06-26 1999-12-30 Hassan Jomaa Bisphosphonsäuren und deren Derivate enthaltende Arzneimittel zur Prophylaxe und zur Behandlung von Autoimmunkrankheiten sowie von Allergien
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
EP1178810B8 (en) * 1999-05-21 2005-07-27 Novartis AG Use of bisphosphonic acids for treating angiogenesis
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
KR100492110B1 (ko) * 2000-05-05 2005-06-02 에프. 호프만-라 로슈 아게 비스포스폰산 또는 그의 염을 포함하는 피하 투여용겔-유사 약학 조성물
DK1296689T3 (da) * 2000-06-20 2005-11-28 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
JP2002332235A (ja) * 2001-02-01 2002-11-22 Riderway Corp 骨疾患治療用液体医薬組成物
ITMI20020908A1 (it) 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione di sodio alendronato
BR0308901A (pt) * 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
WO2003099992A2 (en) * 2002-05-17 2003-12-04 Wyeth Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
ES2530791T3 (es) * 2002-12-20 2015-03-05 Hoffmann La Roche Formulación de ibandronato de altas dosis
US7723542B2 (en) * 2003-12-23 2010-05-25 Trifarma S.P.A. Process for the preparation of alkyl- and aryl-diphosphonic acids and salts thereof
MX2007000087A (es) * 2004-06-23 2007-11-06 Teva Pharma Acido ibandronico solido y cristalino.
EP2610261A1 (en) 2005-02-01 2013-07-03 F. Hoffmann-La Roche AG Ibandronate polymorph B
LT2662380T (lt) 2005-02-01 2019-03-12 Atnahs Pharma Uk Limited Ibandronato polimorfo a medicininis panaudojimas
WO2007074475A2 (en) 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate

Also Published As

Publication number Publication date
CA2576659A1 (en) 2006-03-02
DE202005021414U1 (de) 2008-03-20
WO2006024024A3 (en) 2006-06-29
WO2006024024A2 (en) 2006-03-02
ES2358269T3 (es) 2011-05-09
KR20090120011A (ko) 2009-11-23
EP1930011B1 (en) 2011-08-17
EP1930011A2 (en) 2008-06-11
CN101022812A (zh) 2007-08-22
KR20070043043A (ko) 2007-04-24
EP1713489A2 (en) 2006-10-25
EP1930011A3 (en) 2008-06-18
US7563918B2 (en) 2009-07-21
DE602005025977D1 (de) 2011-03-03
JP2007512237A (ja) 2007-05-17
IL181298A (en) 2011-04-28
US20070179119A1 (en) 2007-08-02
PT1930011E (pt) 2011-09-16
IL181298A0 (en) 2007-07-04
EP1713489B1 (en) 2011-01-19
JP4559431B2 (ja) 2010-10-06
ATE495747T1 (de) 2011-02-15
PT1713489E (pt) 2011-03-03

Similar Documents

Publication Publication Date Title
DE602005025977D1 (de) Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
MY151295A (en) Pyrimidyl indoline compound
TW200738241A (en) Pyridazine derivatives
AR073298A1 (es) Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv.
TW200608972A (en) Aryl-pyridine derivatives
UA83720C2 (ru) Кристаллическая форма v агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит
MY145632A (en) 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethylester-methanesulfonate and its use as a medicament
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
MY141306A (en) New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it
MY142856A (en) New crystalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it
HRP20041092B1 (hr) Novi farmaceutski pripravci flibanserina
GEP20125433B (en) α CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL, PROCESS FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITIONS COMPRISING IT
MY143557A (en) Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it
HRP20110162A8 (hr) Spojevi koji sadrže amlodipin i bisoprolol
TW200616976A (en) Pyrimidine derivatives
MY139704A (en) Naphthalene derivatives for use as histamine-3-receptor ligands
BRPI0519414A2 (pt) composiÇço oral, composiÇço em pasta ou gel, e, mÉtodos para inibir crescimento bacteriano na cavidade oral, e para manter saéde sistÊmica
MX2010001705A (es) Co-cristales de pirimetanilo y ditianona.
TW200616958A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
TW200740764A (en) Pyrazolone derivatives
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
TW200800993A (en) Organic compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties